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The genetic hallmark of acute promyelocytic leukemia (APL) is the t(15;17)(q22;q21)/PML-RARA rearrangement, which is detectable by fluorescence in situ hybridization (FISH) or reverse transcription-polymerase chain reaction (RT-PCR) in 495% of morphologically defined APL. 1, 2 Moreover, seven variant fusion genes, which fuse RARA at low frequency to ZBTB16 or very rarely to NPM1, NUMA1, PRKAR1A, FIP1L1, BCOR and STAT5B have been described. [2] [3] [4] [5] Prolonged disease-free survival of APL patients is achieved by combining all-trans retinoic acid (ATRA) and chemotherapy. 6 In addition, treatment with arsenic trioxide (ATO) is of proven value in relapsed disease and also effective during induction or consolidation therapy or both. [5] [6] [7] However, the RARA fusion partner has an important impact on the biology of the disease, in particular with regard to retinoic acid (RA) sensitivity. Therefore, APL can be divided in two disease subtypes: a RAAccepted article preview online 28 December 2012; advance online publication, 22 January 2013
Letters to the Editor responsive subtype, which includes APL with RARA fusions to PML, NPM1 and NuMA, and possibly also to BCOR, PRKAR1A and FIP1L1; and a RA-unresponsiveness subtype characterized by the presence of the ZBTB16-RARA and most probably the STAT5B-RARA fusions. [1] [2] [3] [4] The sensitivity of variant RARA fusions to ATO has not been well documented, but ZBTB16-RARA-positive APL appears to be resistant. 2, 5 In this respect, it is noteworthy that the direct interaction of ATO with the PML moiety of the PML-RARA fusion protein leading to its degradation may provide an explanation for the specificity of ATO treatment in PML-RARApositive APL. 8 Herein, we describe a new case of APL with a STAT5B-RARA fusion in an adolescent-the first pediatric patient-which brings the number of patients with this rare APL variant to eight. [9] [10] [11] [12] [13] [14] [15] Furthermore, we summarize the therapeutic approaches and clinical data of the cases described so far, demonstrating that patients with STAT5B-RARA-positive APL are unresponsive to both ATRA and ATO. This emphasizes the clinical importance of identifying this specific fusion gene in PML-RARAnegative APL.
A 17-year-old boy underwent a routine checkup for a several day history of fatigue without any other clinical evidence of leukemia. However, 10% and 80% blast cells with AML M3 morphology and prominent Auer rods were detected in the peripheral blood and the bone marrow (BM), respectively. (Figure 1a) , hybridization with the Vysis LSI PML-RARA single fusion FISH probe kit suggested a deletion of RARA (Figure 1b) . FISH employing the RARA-specific cosmid cos124
1 and a STAT5B-specific BAC clone showed one co-localization of the probes (Figure 1c) . Moreover, by applying additional FISH probes loss of genetic material at both loci as well as the presence of an inversion event were observed, indicating a complex intrachromosomal rearrangement. A more detailed description of the FISH data and all probes used are provided in the Supplementary Information. STAT5B-RARA-specific RT-PCR using primers STAT5Bex14-F1 5 0 -GGCAATGGTTTGACGGTGTG-3 0 and RARAex3-R1 5 0 -AGGGAGGGCTGGGCACTATC-3 0 and sequencing of the amplification product confirmed that, like in all cases described so far, 9-15 STAT5B exon 15 was fused to RARA exon 3 ( Figures 1d and e) .
Based on epidemiological data, 495% of APL harbor a PML-RARA rearrangement, and ZBTB16-RARA and NPM1-RARA account for o1% and 0.5% of the cases, respectively. 1 Including the patient described herein, now eight STAT5B-RARA-positive APL cases have been identified; [9] [10] [11] [12] [13] [14] [15] however, due to the lack of epidemiological data the incidence of this APL variant remains to be determined. The median age of the patients was 36.5 years (range 17-67 years), and remarkably, seven of the eight patients were male (Table 1) . A similar biased sex ratio has also been observed in ZBTB16-RARA-positive APL in that amongst 11 adult patients 10 were male. 1 In contrast, PML-RARA-positive APL shows an almost equal sex distribution in both childhood and adult APL. 7, 16 After informed consent was obtained, the patient was treated according to the AML-BFM 2004 (ClinicalTrials.gov: NCT00111345) protocol, 7 and during intensification and maintenance therapy seven courses of ATRA (each for 14 days) were administered. Morphological remission was achieved after induction chemotherapy; however, despite treatment with ATRA, coagulation tests remained abnormal during the first two courses of chemotherapy. Minimal residual disease (MRD) levels determined by flow cytometry, tracking the aberrant CD33 þ þ , CD45RA þ , CD99 þ þ and CD34 À blast cell-specific phenotype (Figure 1f ), declined slowly: 10% at day 15, 0.85% after the second Abbreviations: ATRA, all-trans retinoic acid; alloPBSCT, allogeneic peripheral blood stem cell transplantation; alloSCT, allogeneic stem cell transplantation; ATO, arsenic trioxide; autoSCT, autologous stem cell transplantation; BM, bone marrow; BMT bone marrow transplantation; CR, complete morphological remission; CRf, flow remission; CRm, molecular remission; DIC, disseminated intravascular coagulation:
À none, þ moderate, þ þ severe; FAB, French-American-British; GCS-F, granulocyte colony-stimulating factor; MDS, myelodysplastic syndrome; NA, not available; RCMD, refractory cytopenia with multilineage dysplasia; WBC, white blood cell. a
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Letters to the Editor and 0.06% after the third course of chemotherapy. Two years after diagnosis, the patient had an isolated extramedullary relapse in the right testis that was treated with ATO (50 days) without any response. A decrease of testicular size was achieved with fludarabine, cytarabine and daunoxome; and the testis was removed. Another block of fludarabine and cytarabine was administered, followed by high-dose therapy with treosulfan, fludarabine and thiotepa, as well as autologous stem cell rescue. Three and a half years after initial diagnosis, he had a second isolated BM relapse with blast cells treatment-resistant to fludarabine, cytarabine and amsacrine. Without having achieved a third CR, stem cell transplantation was pursued; however, during conditioning therapy, he died of fulminant pulmonary and cerebral aspergillosis.
Regarding the clinical outcome of STAT5B-RARA-positive APL patients on the whole, we aimed to collect the therapy regimens administered and the most recent follow-up data of all patients described to date. As summarized in Table 1 , all of them were treated with ATRA, and four also with ATO (two each at diagnosis and relapse) combined with different polychemotherapy regimens. Importantly, although administration of ATRA resulted in an improvement of disseminated intravascular coagulation, no differentiation of the blast cells was achieved, emphasizing that STAT5B-RARA-positive APL is unresponsive to ATRA (Table 1) .
More specifically, in patient 2, due to the lack of granulocytic differentiation ATRA therapy was discontinued and only after induction chemotherapy a CR was achieved. A first relapse occurred 9 months after initial presentation, and a second brief CR was obtained with gemtuzumab ozogamicin, followed by non-myeloablative allogeneic stem cell transplantation. However, the patient succumbed to transplantation-related complications. In case 3, polychemotherapy resulted in a CR, however 41 months from diagnosis this patient developed a secondary myelodysplastic syndrome, and after more than 6 years the STAT5B-RARA-positive APL recurred. Patient 4 experienced two relapses, a first extramedullary relapse, and after a short CR, a second relapse in the BM occurred and the patient died of progressive disease. Furthermore, the patient described herein (case 8), who at first extramedullary relapse in the testis received ATO without any evidence of responsiveness, suggests that STAT5B-RARA-positive APL is not only unresponsive to ATRA but also to ATO. Supporting this notion, in case 3 at relapse ATO was not effective, in case 5 despite induction therapy with ATRA and ATO no granulocytic differentiation was observed, and in case 7 neither by the administration of ATRA nor by ATO and polychemotherapy a CR was achieved.
Of particular interest, in case 6 monitoring of MRD by RT-qPCR showed that the patient, although in morphological CR, never obtained a molecular remission. Post-treatment MRD analysis indicated an impending relapse and further therapy followed by allogeneic BMT was given; however, the patient died of transplantation-related complications. In line with the persistent MRD in case 6, flow MRD levels in the patient described herein indicate that no molecular remission might have been obtained. Unfortunately, lack of appropriate material precluded analysis of STAT5B-RARA fusion transcript levels. In view of the clinical importance of detecting persistent molecular MRD at the end of consolidation therapy or recurrent molecular disease in PML-RARA-positive APL patients, 6 assessment of STAT5B-RARA transcript levels by RT-qPCR, 14 which provides a higher sensitivity as compared to flow MRD, will facilitate clinical decision-making regarding allogeneic transplant as well as early treatment intervention at any signs of an impending relapse also in this APL subtype.
In contrast to the overall relapse rate of about 10-15% in APL, 2, 5, 6 86% (6/7) of patients with STAT5B-RARA-positive APL-including one case with a molecular relapse-experienced single or multiple relapses (Table 1) ; and all of them died of transplantation-related complications or progressive disease. Notably, the only patient (case 5) who remains relapse-free for more than 2 years received an allogeneic transplant in first molecular CR. Although in APL the occurrence of extramedullary disease both at presentation and relapse is a rare event, 2, 5, 6 one case each had an isolated CNS and testis relapse. Even at molecular relapse, CNS involvement is not uncommon, which therefore, should be excluded in all APL patients at diagnosis and at molecular or frank relapse. 6 In summary, STAT5B-RARA-positive APL is unresponsive to both ATRA and ATO, belongs to a highly relapse-prone APL subgroup, and its potential refractoriness to chemotherapy at relapse suggests that this subgroup of APL patients might benefit from BM transplantation in first remission. Therefore, the accurate identification of this rare subtype of APL is essential to guide therapeutic decisions.
